Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Melanoma 7Lung Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Pathologic Complete Response 2Pancreatic Neoplasms 2Neoplasm, Residual 2Hyperthermia 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Radiation Pneumonitis 1

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2-Negative Locally Advanced Breast Cancer × Immunotherapy × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡